Aptevo Therapeutics Stock Today
| APVO Stock | USD 0.28 0.07 20.00% |
Performance2 of 100
| Odds Of DistressOver 85
|
Aptevo Therapeutics is selling at 0.28 as of the 2nd of December 2024; that is 20 percent decrease since the beginning of the trading day. The stock's open price was 0.35. Aptevo Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Aptevo Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of September 2024 and ending today, the 2nd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of July 2016 | Category Healthcare | Classification Health Care |
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. The company has 18.51 M outstanding shares of which 734.63 K shares are presently shorted by private and institutional investors with about 0.05 trading days to cover. More on Aptevo Therapeutics
Moving against Aptevo Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Aptevo Stock Highlights
| CEO President | Marvin White | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAptevo Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aptevo Therapeutics' financial leverage. It provides some insight into what part of Aptevo Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aptevo Therapeutics (APVO) is traded on NASDAQ Exchange in USA. It is located in 2401 4th Avenue, Seattle, WA, United States, 98121 and employs 40 people. Aptevo Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.39 M. Aptevo Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 18.51 M outstanding shares of which 734.63 K shares are presently shorted by private and institutional investors with about 0.05 trading days to cover.
Aptevo Therapeutics currently holds about 29.43 M in cash with (11.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Aptevo Therapeutics Probability Of Bankruptcy
Ownership AllocationAptevo Therapeutics holds a total of 18.51 Million outstanding shares. Almost 88.62 percent of Aptevo Therapeutics outstanding shares are held by general public with 0.028 (percent) owned by insiders and only 11.36 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Aptevo Ownership Details
Aptevo Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 194 | |
| Bank Of America Corp | 2024-06-30 | 160 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 45.0 | |
| Jpmorgan Chase & Co | 2024-09-30 | 43.0 | |
| Wells Fargo & Co | 2024-09-30 | 33.0 | |
| Pnc Financial Services Group Inc | 2024-09-30 | 3.0 | |
| Truvestments Capital Llc | 2024-09-30 | 2.0 | |
| Baader Bank Inc | 2024-09-30 | 0.0 | |
| Ubs Group Ag | 2024-09-30 | 0.0 | |
| Hudson Bay Capital Management Lp | 2024-09-30 | 935.6 K | |
| Sabby Management Llc | 2024-06-30 | 501.5 K |
Aptevo Therapeutics Historical Income Statement
Aptevo Stock Against Markets
Aptevo Therapeutics Corporate Executives
Elected by the shareholders, the Aptevo Therapeutics' board of directors comprises two types of representatives: Aptevo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aptevo. The board's role is to monitor Aptevo Therapeutics' management team and ensure that shareholders' interests are well served. Aptevo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aptevo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daphne Taylor | Senior CFO | Profile | |
| Daphne CPA | Senior CFO | Profile | |
| Jeffrey CA | Executive COO | Profile |
Already Invested in Aptevo Therapeutics?
The danger of trading Aptevo Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aptevo Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aptevo Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aptevo Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aptevo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptevo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptevo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptevo Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.24) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (2.51) |
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.